Defense Advanced Research Projects AgencyTagged Content List

Threat Countermeasures

Actions that mitigate adversaries' capabilities

Showing 87 results for Countermeasures RSS
DARPA’s Mobile Force Protection (MFP) program focuses on a challenge of increasing concern to the U.S. military: thwarting the proliferation of small, unmanned aircraft systems. These systems – which include fixed- or rotary-wing aircraft and have numerous advantages such as portability, low cost, commercial availability, and easy upgradeability – pose a fast-evolving array of dangers for U.S. ground and maritime convoys.
The Nucleic acids On-demand Worldwide (NOW) program aims to develop a mobile medical countermeasure (MCM) manufacturing platform for use in stabilization and humanitarian operations to rapidly produce, formulate, and package hundreds of doses of nucleic acid therapeutics (DNA and/or RNA).
The Pandemic Prevention Platform (P3) program aims to support military readiness and global stability through pursuit of novel methods to dramatically accelerate discovery, integration, pre-clinical testing, and manufacturing of medical countermeasures against infectious diseases. P3 confronts the reality that Department of Defense (DoD) personnel are not only deployed around the world for routine operations, but are often among the first responders to outbreaks of emerging or re-emerging disease with pandemic potential (e.g., Ebola). P3 aims specifically to develop a scalable, adaptable, rapid response platform capable of producing relevant numbers of doses against any known or previously unknown infectious threat within 60 days of identification of such a threat in order to keep the outbreak from escalating and decrease disruptions to the military and homeland.
The Pathogen Predators program focuses on force readiness and homeland protection through development of novel countermeasures against biological threats involving bacterial agents. Currently, the most common defense against such a threat is traditional antibiotics, but while such antibiotics have been remarkably effective in the past, their widespread use has heightened the risk of our troops contracting antibiotic-resistant bacterial infections that are difficult or impossible to treat. A new type of countermeasure is needed to overcome the threat posed by antibiotic-resistant bacteria.
Pathogens with pandemic potential, toxic chemicals, and radioactive materials all endanger public health and pose a threat to national security. Despite investment in the development of medical countermeasures (MCMs) to address these threats, many existing MCMs suffer from limited applicability, insufficient efficacy, requirements for repeat dosing, lengthy and complex manufacturing processes, and logistically burdensome storage requirements. In many cases, unique threats require unique responses, setting up a “one threat, one MCM” paradigm.